ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Broader Chemical Distribution By NCI Awaits Hew Bureaucracy; Recipients May Have To Pay

March 2, 1979

NIH Defines Misconduct

December 9, 1994

Budget Would Support 1,211 More Grants

February 7, 2003

Garb Denies He, Panel Said Contract Should Be Primary Funding Mechanism

March 17, 1978

Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.

November 22, 2006

In Brief: Mary Lasker To Be Named To NIH Director’s Advisory Committee; Amos Appointment Official

July 18, 1980